Drug selection for breast cancer therapy using antibody-based arrays
AU2013205274A1
Drug selection for breast cancer therapy using antibody-based arrays
WO2012158831A1
Performance of a biomarker panel for irritable bowel syndrome
WO2012075333A2
Her2delta16 peptides
BR112012012513A2
method for diagnosing irritable bowel syndrome in a patient, method for monitoring the progression or regression of irritable bowel syndrome in a patient, and for assigning irritable bowel syndrome therapy to a patient in need thereof
WO2011060098A1
Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
CN102712956A
Methods for diagnosing irritable bowel syndrome
KR20120108978A
Assays for the detection of anti-tnf drugs and autoantibodies
CN102667478A
Proximity-mediated assays for detecting oncogenic fusion proteins
CA2761777A1
Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
EP2359137A2
Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
CN102016581A
Drug selection for breast cancer therapy using antibody-based arrays
US2010094560A1
Methods for diagnosing irritable bowel syndrome
BRPI0717416A2
Method for performing a high productivity complex immunoason, and
US2008085524A1
Methods for diagnosing irritable bowel syndrome
US2007254295A1
Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7943328B1
Method and system for assisting in diagnosing irritable bowel syndrome
US2008131439A1
Methods of diagnosing inflammatory bowel disease
US2007093497A1
Methotrexate compliance packaging
US2006286571A1
Methods of predicting methotrexate efficacy and toxicity
